Themis Medicare Ltd has developed a global first of its kind product Aceclofenac injection, which is covered by IPR. The company has conducted multi-centric clinical trials and has received manufacturing and marketing permissions from the Drug Control authorities as also from the State authorities.

The company is marketing the product under its own brand name and has also entered into long-term agreements with Zydus Cadila as well INTAS that will market the same under their own brand names.

Many other companies too have requested for the license to market the product and the company is in the process of scrutinizing the requests.